About Us
Renovaro Biosciences is driven by a steadfast commitment to revolutionize healthcare.
What we do
Renovaro Biosciences is driven by a steadfast commitment to revolutionize healthcare.
Our primary goals encompass pioneering advancements in biotechnology to develop groundbreaking therapies and diagnostic tools.
We aim to address unmet medical needs in diverse areas such as oncology, neurology, infectious diseases, and rare genetic disorders.
a future free from toxic chemo- therapy
Our goals
By fostering global collaborations, we seek to accelerate the translation of scientific breakthroughs into tangible solutions, positively impacting lives worldwide.
Renovaro is dedicated to creating a healthier and more resilient future for humanity through innovation, ethical practices, and a relentless pursuit of excellence in biotechnology.
Our latest news
April 24, 2024
RenovaroCube to Acquire 100% Ownership of Cyclomics
RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment.
April 18, 2024
Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board
This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies.
February 14, 2024
Statement of Renovaro Inc
We felt compelled to comment on the shorter Hindenburg’s opinion piece.
February 13, 2024
Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.
